AngioGenex Inc
AGGX
Other OTC0.00
USD
- -
- -
Return %
Stock
S&P500
1Y
-50.00
26.53
3Y
-50.00
76.60
5Y
-50.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Jan 29, 2007
- Similar Companies
- Business
- AngioGenex Inc (AGGX) is a biopharmaceutical company focused on the discovery and development of Id protein inhibitors to address unmet medical needs in oncology and ophthalmology; its platform leverages proprietary technologies and tools, including collaborations with The Robert Benezra Lab at Sloan Kettering Institute, for identifying specific small molecule binders of Id proteins, which play key roles in tumor angiogenesis, metastasis, and pathological vascularization in ocular diseases. The company's core pipeline includes AGX-A, a novel small molecule Id inhibitor under investigation for cholangiocarcinoma, a form of liver cancer, and age-related macular degeneration; it also pursues Id-based diagnostics, such as sensitive blood assays for cancer detection, prognosis, and patient monitoring in collaboration with partners like BioCheck Inc. Founded in 1999 and headquartered in New York, NY, AngioGenex operates primarily in the United States with a focus on translational research from Memorial Sloan Kettering Cancer Center, targeting solid tumors and vascular eye disorders through small molecules, antisense/siRNA approaches, and proprietary Id gene knockout models. Recent developments include a private placement funding round of $0.3 million closed in December 2021 to support ongoing research; a February 2020 announcement of co-development efforts for anti-cancer drugs with Memorial Sloan Kettering; and historical strategic merger with eClic Inc in 2006 to achieve public company status, alongside exclusive worldwide licenses from MSKCC for Id-targeted therapeutics and diagnostics.